Search results
5 sie 2022 · Evaluate the underlying cause or causes of hyperbilirubinemia in infants who require phototherapy by obtaining a DAT in infants whose mother had a positive antibody screen or whose mother is blood group O regardless of Rh(D) status or whose mother is Rh(D)−.
- Getting Out of The Gate
In theory, clinical practice guidelines (CPGs) are designed...
- Getting Out of The Gate
Highlights the challenge of identifying G6PD deficiency in infants. Bases follow-up testing on the difference between bilirubin level and the phototherapy threshold. No more risk zones! Raises thresholds for phototherapy and exchange transfusion.
INSTRUCTIONS. Use in otherwise healthy neonates ≥35 weeks gestational age (GA) at the time of discharge. Do not use in neonates with positive direct Coombs test, or in those requiring phototherapy before 60 hours of age. Do not use to determine need for exchange transfusion.
Calculator and clinical decision support for the AAP 2022 guidelines for the management of hyperbilirubinemia in newborns 35 or more weeks of gestation. Features. Neurotoxicity risk factors absent, present, or both. Plot multiple time points to assess trends.
Guidelines for Phototherapy. Use total bilirubin. Do not subtract direct (conjugated) bilirubin. Risk factors = isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3g/dL.
1 maj 2021 · The American Academy of Pediatrics recommends using a graph of predischarge total serum bilirubin (TSB) levels by age (the Bhutani Nomogram) to aid in determining timing of follow-up and a different graph to determine phototherapy recommendations.
History. Assess all newborns for risk factors for developing hyperbilirubinemia (Table 1). Table 1. Neurotoxicity Risk Factors. Bilirubin Measurement. A total bilirubin (TSB or TcB) level should be measured on all newborns prior to discharge. [I-C*] Choose appropriate test for bilirubin levels (Table 4).
